News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
About the Author - Alex Keown

news@biospace.com

BioSpace News - By Alex Keown
FDA Approves Biogen (BIIB) and AbbVie (ABBV)'s Once-Monthly MS Drug Zinbryta 5/31/2016
Jazz Pharma (JAZZ) Pays $1.5 Billion for Celator Pharma (CPXX) to Gain a Promising Leukemia Drug 5/31/2016
Merck & Co. (MRK), Pfizer (PFE) and Others Join Forces to Fight California Drug Price Control Ballot Initiative 5/31/2016
Genentech (RHHBY)’s Gazyva Meets Primary Endpoint Early in Late-Stage Study 5/27/2016
Embattled Valeant (VRX) Reportedly Spurned a Takeover Offer from Takeda (TKPYY)-TPG 5/27/2016
Thermo Fisher Scientific (TMO) Expands into Pharma Market, Antes Up $4.2 Billion for FEI Company 5/27/2016
Only One Week After Voiding Two Years of Tests, Theranos Now Faces Consumer Class Action Lawsuit 5/27/2016
Ionis Pharma (IONS) Plummets After GlaxoSmithKline (GSK) Opts Not to Initiate Phase III Study for Amyloid Cardiomyopathy Drug 5/27/2016
Walgreens' Execs Ignored Doubts in Theranos' Technology in Fear of Deal Crumbling 5/27/2016
Retired Gilead (GILD) Exec Returns as His Replacement Exits 5/26/2016
Count Celgene (CELG) and Gilead (GILD) as New Suitors to Acquire the Popular Medivation (MDVN) 5/26/2016
Sophiris Bio (SPHS) Slashes Workforce in Half as Firm Explores Strategic Options 5/25/2016
Novartis AG (NVS) CEO Attempts to Rebuild as Seven Execs Jump Ship in the Space of Five Months 5/25/2016
Sanofi (SNY) Loses Three Top Execs, Reshuffles Executive Committee 5/24/2016
French Authorties Blame Both Biotrial and Bial Over Fatal Drug Trial 5/24/2016
M&A Targets Pfizer (PFE) and Others Could be Eyeballing 5/24/2016
Novartis AG (NVS)'s Pharma Head Exits as Drug Business is Split into Two 5/24/2016
10 Biotech Stocks Analysts are Upbeat About in May 5/23/2016
Fearless Theranos Eyes Expansion Despite Dealing with One Setback After Another 5/23/2016
NeuralStem to Cut an Unknown Number of Jobs in Reorganization 5/20/2016
Journalist Criticizes ZIOPHARM Oncology (ZIOP.OB) as Its Own ‘Biotech Bubble’ Held Aloft by Ties to R.J. Kirk's Intrexon (XON) 5/20/2016
About 500 Kendall Square Baxalta (BXLT) Staffers in Limbo as Shire (SHPG) Merger Talks Drag On 5/20/2016
3 Life Science Stocks Short-Sellers are Wrong About 5/20/2016
Embattled Theranos Tosses Out Two Years of Edison Blood Test Results 5/20/2016
AstraZeneca PLC (AZN) Hands Out Pink Slips to Unknown Number of Contract Sales Reps 5/19/2016
Enterome Opens Up U.S Office in Kendall Square 5/19/2016
AstraZeneca PLC (AZN) CEO's Big Experiment and His Take on Keeping Employees on Edge 5/19/2016
3 Biotech Stocks Investors Should Pick Up in May 5/18/2016
Navidea (NAVB) Shakeup Continues as CEO Rick Gonzalez is Now Out 5/18/2016
New York Could Be Next Booming Bio Hub as Cellectis (ALCLS), Pfizer (PFE) and Eli Lilly (LLY) Set Up Shop There 5/18/2016
Catalyst Pharma (CPRX) Axes 30% of Workforce to Conserve Cash 5/18/2016
Biogen (BIIB) Aligns with Two Super Stars and Bags a Deal with REGENXBIO in Gene Therapy Push 5/17/2016
Journalist Claims Intrexon (XON) CEO is Untrustworthy, Compares Firm to Theranos 5/17/2016
Theranos COO Abruptly Resigns, Company Adds New Board Members 5/17/2016
Aduro Biotech (ADRO)'s Stock Craters After Pancreatic Cancer Drug Trial Misses Primary Endpoint 5/17/2016
Bay Area's KineMed Files for Chapter 11, Owes $1 Million+ to NIH, Gates and Others 5/16/2016
Gutsy Sanofi (SNY) to Nominate 8 Directors for Medivation (MDVN) Board, Files Pre-Merger Papers 5/13/2016
Federal Agencies Want to Know More About Clovis Oncology (CLVS)'s Rociletinib Data from Last Fall 5/13/2016
Valeant (VRX)'s New CEO Criticized By Man Who Succeeded Him at Perrigo (PRGO) 5/13/2016
Chiasma Chief Says Firm May Challenge FDA Over Rare-Disease Drug Rejection 5/12/2016
Genentech (RHHBY) May Owe Refunds to Some Healthcare Providers Over 340B Price Violations 5/12/2016
Allergan (AGN) Reworking Its Executive Team, Outlines $10 Billion Stock Buyback as Q1 Revenue Falls Short 5/12/2016
Another Director, Accounting Firm Quit Navidea (NAVB), Lender Tried to Freeze Its Bank Accounts 5/11/2016
Pernix (PTX) CEO Steps Down, Effectively Immediately 5/11/2016
Bay Area's Alexza Pharma (ALXA) Sold in $35 Million Deal 5/11/2016
San Diego's Sorrento (SRNE) Hires Advisors to Mull Over Strategic Options 5/10/2016
AstraZeneca PLC (AZN) Employees from Shuttered Facility Could be Relocated to Delaware 5/10/2016
RXi Pharma (RXII) to Explore Strategic Options, Including Possible M&A 5/10/2016
BioDelivery (BDSI) Consolidating the Sales Force Size in Cost-Cutting Move 5/10/2016
Wildcat Capital Calls for Ouster of Sorrento (SRNE)'s CEO, Accuses Firm of Squandering Assets and Destroying Shareholder Value 5/9/2016
A Look at 4 People Molding Kendall Square's Future 5/9/2016
Investors Concerned as Endo Pharma (ENDP) Mimics the Path of Valeant (VRX) 5/9/2016
Endo Pharma (ENDP) to Cut 740 Employees and Shakes Up U.S. Senior Management in Restructuring 5/9/2016
Clovis Oncology (CLVS) to Eliminate 35% of Workforce and Ends All Trials of Lung Cancer Drug Rociletinib 5/9/2016
Look Who Google (GOOG)'s Verily Is Hiring 5/6/2016
Amgen (AMGN) Rumored to be Another Medivation (MDVN) Suitor 5/6/2016
Apple (AAPL) Taps Former Google X Cofounder for Health Push 5/6/2016
10 Massachusetts Biotechs Devoting the Most Cash to R&D 5/6/2016
Look Who’s Profiting from Gilead (GILD)'s Sky-High Hepatitis C Drug Prices 5/6/2016
Investors Disappointed as Merck & Co. (MRK) Sales of Januvia and Remicade Fall Short 5/5/2016
Booming Bay Area Biotech NGM Plans Move to Vacant Site Once Meant for Amgen (AMGN) 5/5/2016
Theranos Allegedly Sent Team of Five Lawyers to Wall Street Journal to Squash Story 5/4/2016
3 Bargain Biotechs to Buy 5/4/2016
IMS Health, Quintiles (Q) to Merge to Form $23 Billion Power House 5/4/2016
Backed by Celgene (CELG) and Novartis AG (NVS), IDEAYA Biosciences Raises $46 Million and Recruits an Arsenal Full of Industry Vets 5/4/2016
Delaware Employees Nervous Over AstraZeneca PLC (AZN)'s $1 Billion Cost-Cutting Plans 5/4/2016
Federal Judge Reopens Gilead (GILD) Case Amid Allegations Former Merck & Co. (MRK) Scientist Lied 5/3/2016
Cambridge's BIND Therapeutics (BIND) Files for Chapter 11 and Reviews Strategic Alternatives 5/3/2016
North Carolina's NephroGenex (NRX) Files for Chapter 11 and Seeks Sale 5/2/2016
Federal Health Regulators Release Lightly Redacted Theranos Report with More Details 5/2/2016
Sienna Biopharma Launches with $34 Million and a Roster Full of Former Kythera (KYTH) Execs 5/2/2016
FDA Sued for Not Disclosing More Info on the Experts Determining the Fate of Drugs and Devices 4/29/2016
Vertex (VRTX) CEO Took a 23% Pay Cut in 2015 as Firm Overhauls Compensation Policies 4/29/2016
Life Science Real Estate Developer Lands $310 Million Construction Loan for Cambridge R&D Project 4/29/2016
Biogen (BIIB) Poaches Star Pfizer (PFE) Scientist as New R&D Chief 4/29/2016
Alnylam (ALNY) Breaks Ground on New $200 Million Manufacturing Facility in Massachusetts, Adding 150 Jobs 4/29/2016
NantKwest CEO's $329.7 Million Pay Package Might Make Him the Highest-Paid U.S. Executive 4/29/2016
Pennsylvania’s Inovio Pharma (INO) Doubles Workforce, Continues Hiring Spree 4/28/2016
Valeant (VRX)'s New CEO Will Make Over $500 Million if Stock Hits $270 By 2020 4/28/2016
Backed by Celgene (CELG), Bay Area Startup FLX Bio Bags $50 Million to Push Lead Drug into Clinic 4/28/2016
Aurobindo Pharma (AUROBINDOP.BO) Adding 275 Jobs in Durham Despite Backlash Over LGBT Law 4/27/2016
Perrigo (PRGO) Names New CEO as Joseph Papa Joins Rival Valeant (VRX) 4/27/2016
ImmunoGen (IMGN) Taps Former Shire (SHPG) Exec as New CEO 4/27/2016
Seattle’s Adaptive Biotech Looks to Hire 50 Employees in 2016 to Buttress Fast Growth 4/26/2016
Allergan (AGN) Finally Breaks Ground on $200 Million Texas Expansion, Facility to Up Headcount by 100 4/26/2016
Critics Believe New Valeant (VRX) CEO Joe Papa Jumped from One Troubled Drugmaker to Another 4/26/2016
From 20 to 84 Employees in Just Four Years, Booming Blueprint Medicines (BPMC) Maps Out a Plan 4/26/2016
Deal Spree for AbbVie (ABBV) Continues with $500 Million Cancer Tie-Up with Bay Area's CytomX 4/25/2016
Eisai Company (ESALY.PK) Beefs Up Neurology Team with Ex-Pfizer (PFE), Sanofi (SNY) Execs 4/25/2016
Juno (JUNO), Five Prime (FPRX) are Quiet Winners at AACR 4/25/2016
Alere (ALR) Stock Falls as Abbott (ABT) CEO Declines to Comment and Confirm $6 Billion Deal 4/22/2016
Valeant (VRX) Close to Naming Perrigo (PRGO)'s Joseph Papa as New CEO 4/22/2016
AbbVie (ABBV) Gets First Dibs on arGEN-X's Immuno-Oncology Drug in Deal Worth $685 Million 4/21/2016
Novartis AG (NVS)'s U.S. Head Steps Down for Personal Reasons 4/21/2016
Argos (ARGS) Slashes 13% of Workforce to Complete a Phase III Study Under Budget, COO Resigns 4/21/2016
Theranos Director Defends Elizabeth Holmes, Says CEO is "Clearly Equipped" to Run Company 4/21/2016
Astex Pharma (ASTX) and Genentech (RHHBY) Forge a Clinical Trial Deal for Acute Myeloid Leukemia 4/20/2016
Bay Area’s GigaGen Develops Synthetic Immune System to Harness Antibodies 4/19/2016
Covered in $30 Billion Debt, Embattled Valeant (VRX) Mulls Over Which Assets to Sell 4/19/2016
Daiichi Sankyo Picks Location for New U.S. Headquarters 4/19/2016
Sanofi (SNY) to Drop $339 Million on Expansion of Belgium Biologics Drug Site 4/19/2016
Eli Lilly (LLY) Abandons Development of Transition Therapeutics (TTH.TO)' Diabetes Candidate TT401 4/19/2016
More Trouble for Elizabeth Holmes and Theranos as Federal Authorities Launch Criminal Probe 4/19/2016
Osiris (OSIR) Fires CMO Jon Hopper 4/18/2016
North Carolina’s Rho Looks at Untapped Talent Pools to Fill Jobs at Growing CRO 4/18/2016
Embarrassed by "Sexist" Biotech Party, LifeSci Promotes Gender Equality, Hires More Women 4/18/2016
Feds Propose Banning Theranos CEO Elizabeth Holmes from the Blood Testing Biz for at Least Two Years 4/18/2016
Bay Area's Carbylan to Suspend Clinical Development of Hydros-TA and Slash Jobs to Conserve Cash 4/15/2016
3 Biotechs Might Have M&A Targets On Their Backs 4/15/2016
Embattled Valeant (VRX) Working with Banks to Review Options Amid Interest from Buyout Firms 4/15/2016
Booming Seres Therapeutics Looks to Move Lead Product into Phase III, Expand in Cambridge 4/14/2016
Cydan Churns Out Second Rare Disease Biotech Imara with $31 Million 4/14/2016
India's Aurobindo Pharma (AUROBINDOP.BO) is Being Courted to Bring 200 Well-Paying Jobs to the City of Durham 4/14/2016
Clovis Oncology (CLVS) Takes Another Hit After An FDA Panel Votes Against Rociletinib 4/14/2016
Facebook, Napster Trailblazer Sean Parker Wagers $250 Million to Launch Cancer Immunotherapy Institute 4/14/2016
Fresh Off Its $1.2 Billion Deal, Gilead (GILD) Has Cash to Go Shopping Again 4/13/2016
Struggling Ariad (ARIA)'s Luck Might be Turning Around as Company Eyes Pfizer (PFE)'s ALK Space 4/13/2016
Valeant (VRX) Stock Falls on Default Fears, U.S. Rep. Criticizes Company Over Philidor 4/13/2016
Gilead (GILD) Seeks to Build Six-Story Lab in HQ Expansion, May House Up to 5,000 New Employees 4/12/2016
3 Depressed Biotechs that Investors with a Long-Term Perspective Should Buy Right Now 4/12/2016
Peter Thiel-Backed South San Francisco Firm Counsyl Cuts 27 Employees 4/12/2016
Juno (JUNO) Goes Global With Launch of New China-Based JW Biotechnology (Shanghai) Co. 4/11/2016
Theranos Takes a Shot at Redemption by Adding Experts to the Medical Board 4/11/2016
Valeant (VRX)’s Ackman Says Company Will Not Sell Bausch & Lomb 4/8/2016
Massachusetts’ Booming Cytel Hiring and Growing Fast in CRO Role 4/8/2016
Ackman Says New Valeant (VRX) CEO Will be Named Within Weeks 4/7/2016
Durham's Heat Biologics Slashes 22% of Workforce and Cuts Execs' Pay to Conserve Cash 4/7/2016
Baxter International (BAX) to Shut Down Denver Facility, 400 Employees Affected 4/7/2016
Shift in R&D Strategy Forces BIND Therapeutics (BIND) to Slash 38% of Workforce, Look for New Capital and Deals 4/7/2016
Apricus Biosciences (APRI) Axes 30% of Workforce, Discontinues Fispemifene Clinical Programs 4/6/2016
Replicel Life Sciences Downsizes Staff and Non-Clinical Programs to Conserve Cash 4/6/2016
Sprout Team Withers as Valeant (VRX) Terminates 140 Sales Contractors for the Female Libido Drug 4/6/2016
Two Stocks That May be Better Picks than Regeneron (REGN) 4/5/2016
Family-Run Drugmaker Jacobus Pharma Fights to Stay Alive in the Martin Shkreli Era of High Priced Drugs 4/5/2016
Booming Juno (JUNO) May Leave Washington if Policy Makers Continue to Ignore Biotech Incentives 4/5/2016
Bay State Startup Entasis Banks $50 Million Series B 4/5/2016
Gilead (GILD) Finally Makes a Buy, Snaps Up Massachusetts' Nimbus Apollo in $1.2 Billion Deal 4/4/2016
Alnylam (ALNY)’s John Maraganore Provides Leadership for RNAi Development and Biotech Industry 4/4/2016
Janssen R&D Discontinues Fulranumab Phase III Program; Terminates Agreement with Amgen (AMGN) 4/4/2016
Massachusetts Biotech Companies Debate Innovative Pricing Structures for Transformative Medicines 4/4/2016
Federal Report Reveals Theranos Devices Often Failed Accuracy Requirements 4/4/2016
1,000+ Women are Suing Johnson & Johnson (JNJ) for Allegedly Covering Up Baby Powder Cancer Risk for Decades 4/1/2016
New Jersey's Braeburn Pharma May Pull Plans for North Carolina Facility Over LGBT Discrimination Law 4/1/2016
Novartis AG (NVS)'s "Sham Events" Could Affect North Carolina Doctors 4/1/2016
Novartis AG (NVS) Investigates $85 Million Bribery Allegations Made By an Anonymous Whistleblower in Turkey 3/31/2016
SEC Fines and Bans Once Prominent Bay Area Investor Steven Burrill Over Stolen Investor Funds 3/31/2016
Ariad (ARIA) Cuts Another 25% of Workforce at HQ 3/31/2016
Feds Slap AVEO Oncology (AVEO) with $4 Million Fine for Misleading Investors About Cancer Drug 3/30/2016
Sun Pharma (SUNPHARMA.NS) Snaps Up 14 Japanese Brands From Novartis AG (NVS) in $293 Million Deal 3/30/2016
Gilead (GILD) Lost Top Cancer Scientist Right Before Zydelig Troubles Hit 3/30/2016
Theranos Hit Again as New Study Shows Firm's Tests Aren't as Reliable as Standard Tests 3/29/2016
CRO Rho Continues Hiring Spree in North Carolina 3/29/2016
U.S. Alleges Novartis AG (NVS) Hosted 80,000 ‘Sham’ Events to Wine and Dine Doctors to Prescribe Drugs, Seeks Records 3/28/2016
FDA Scorns Eagle Pharma (EGRX)'s Seven Year Orphan Drug Exclusivity Request for Blood Cancer Drug BENDEKA 3/28/2016
Despite a Streak of Bad Luck, Gilead (GILD) Clinches Deal for Foster City HQ Expansion 3/28/2016
Ex-Apple (AAPL) Exec Launches At-Home Blood Test Startup in San Francisco 3/28/2016
Vaxart Pins Hopes on Oral Zika and Flu Virus Vaccines 3/25/2016
Gilead (GILD) Ordered to Pay Merck & Co. (MRK) $200 Million in Damages Over Hep C Patent Dispute 3/25/2016
Biogen (BIIB), Dow Chemical  (DOW), Bayer (BAY) Condemn New N.C. Blocking Measures to Protect LGBT People 3/25/2016
PTC Therapeutics (PTCT) Chops 18% of Workforce 3/24/2016
10 Massachusetts Biotechs that Grew Their Headcount by at Least 40% in 2015 3/24/2016
FDA Bans Clinical Trial Coordinator Who Created Fake Patients and Pocketed Money for Trial Participants 3/24/2016
More Bad Luck for Gilead (GILD) as Merck & Co. (MRK) Wins Victory in Hep C Patent Dispute 3/24/2016
SAGE Therapeutics (SAGE) Tanks as Hedge Fund Kerrisdale Capital Bets Lead Drug Will Fail Phase III Study 3/23/2016
Hillary Clinton Campaign Distances Itself from Embattled Theranos 3/23/2016
Janssen Research & Development, Genentech (RHHBY) Forge Clinical Trials Agreement 3/23/2016
City of Carlsbad Biotech Incubator a Success 3/23/2016
Presidential Contender Bernie Sanders Asks the U.S. Treasury to Block Pfizer (PFE)'s Major Tax Evasion 3/22/2016
Valeant (VRX) Hunts for a New CEO, Blames Former CFO Schiller for Recent Financial Misstatements 3/21/2016
Intrexon Realigns Responsibilities, COO and Sr. Product Development Step Down 3/21/2016
Seattle's Adaptive Biotech to Base New Business in San Diego with Ex-Johnson & Johnson (JNJ) Exec in Charge 3/21/2016
Rumors Swirl as Eli Lilly (LLY) Chairman John Lechleiter Visits Samsung Drug Companies 3/21/2016
Eagle Pharma (EGRX) Plunges as the FDA Rejects Blood Thinner Kangio 3/18/2016
Valeant (VRX) CEO Reassures Employees Firm Isn't Going Broke Even After Stock Continues its Nosedive 3/18/2016
San Francisco-Based McKesson (MCK) Eliminates 1,600 U.S. Jobs to Trim Costs 3/18/2016
Gilead (GILD) Shuts Down Six Zydelig Trials Following European Medicines Agency Review 3/17/2016
Theranos CEO Set to Host Hillary Clinton Fundraiser 3/17/2016
FDA Makes One Small Regulatory Change in Effort to Stop the Next Martin Shkreli 3/17/2016
GlaxoSmithKline (GSK) CEO Sir Andrew Witty to Step Down in 2017 3/17/2016
Bay Area Startup DiCE Molecules Inks Small Molecule Deal Worth Up to $2.3 Billion with Sanofi (SNY) 3/17/2016
Investigation Finds Ex-Provectus CEO Did Not Produce Travel Documentation, May Have Altered Receipts 3/16/2016
Bayer (BAY) Opens Innovation Center in Boston 3/15/2016
Bad News for Bay Area's Five Prime (FPRX) as GlaxoSmithKline (GSK) Walks Away from Cancer Drug Pact 3/15/2016
Gilead (GILD)'s Zydelig Under Review in Europe Following Reported Deaths, Side Effects When Combined With Other Drugs 3/15/2016
Interview with GlaxoSmithKline (GSK)'s Possible Successor to CEO Andrew Witty 3/15/2016
Takeda (TKPYY) Sells U.S. Rights to Contrave Back to Orexigen (OREX), Establishes New Business Units 3/15/2016
AstraZeneca PLC (AZN) Seeks Ways to Link CEO and Top Execs' Pay to $45 Billion Sales Target 3/14/2016
Embattled Bay Area XOMA  (XOMA) Terminates Gevokizumab Trials 3/14/2016
Regeneron (REGN), Sanofi (SNY)'s RA Drug Beats AbbVie (ABBV)'s Blockbuster Humira in Phase III Study 3/14/2016
Theranos Rival HealthTell Bags $26 Million for Single-Drop-of-Blood Diagnostics 3/11/2016
Valeant (VRX) CEO Lays Out Strategy to Staff, Says ‘No Other Shoe Expected to Drop’ 3/11/2016
New Hemispherx (HEB) CEO Will Not Receive Salary for Two Months Until Stock Performs Better 3/11/2016
Google (GOOG)'s Verily Unveils Device to Gather Health Info of People Participating in Clinical Trials in Filing 3/11/2016
Investors Hold Their Breath for Data from Aduro Biotech (ADRO), Novartis AG (NVS) 3/11/2016
Novartis AG (NVS)'s Sandoz to Consolidate Two N.Y. Manufacturing Sites, No Job Losses Expected 3/10/2016
Editas Medicine Stock Surge Driven by Supportive Friends and Their Bank Accounts 3/10/2016
Internal Memo Reveals Bristol-Myers Squibb (BMY) to Stop Paying Speaker Fees to Doctors in China Due to Possible Violations of Company Policies 3/9/2016
Bay Area's Tizona Therapeutics Emerges from Stealth Mode with $70 Million Total in Financing 3/9/2016
Acerus (TRLPF) Founder Sues Company Over 'Gross Mismanagement' 3/9/2016
Breast Cancer Pipeline Has More than 1,000 Drugs in Development 3/9/2016



//-->